The optimal duration of dual antiplatelet therapy (DAPT) for patients implanted with new-generation drug-eluting stents in East Asians is currently still controversial. The purpose of this meta-analysis was to investigate the efficacy and safety of short-term DAPT in patients with those. In this study, randomized controlled trials from PubMed, EMBASE, and Cochrane Library were searched to compare the efficacy and safety of short-term DAPT (6 months or less) with long-term DAPT (12 months or more) in patients implanted with new-generation drug-eluting stents in East Asian from inception to September 2020. The primary efficacy outcome was all-cause death, the primary safety outcome was major bleeding, and the secondary outcomes included cardiovascular death, myocardial infarction, definite or possible stent thrombosis, and stroke. A total of 6 randomized controlled trials with 15,688 patients met inclusion criteria; there were no significant differences in the incidence of all-cause death [risk ratio (RR), 1.03; 0.76–1.39; P = 0.856)], cardiovascular death (RR, 0.83; 0.55–1.24; P = 0.361), myocardial infarction (RR, 0.97; 0.72–1.31; P = 0.853), definite or possible stent thrombosis (RR, 1.52; 0.83–2.78; P = 0.170), and stroke (RR, 0.90; 0.61–1.31; P = 0.574) between short-term and long-term DAPTs. However, there was a significant difference in the risk of major bleeding (RR, 0.64; 0.49–0.85; P = 0.002) between the 2 groups. Compared with long-term DAPT, the short-term DAPT can reduce the risk of major bleeding without increasing the risk of death or ischemia for East Asians (Registered by PROSPERO, CRD42020213266).

对于东亚人植入新一代药物洗脱支架的患者，双联抗血小板治疗（DAPT）的最佳持续时间目前仍存在争议。本荟萃分析的目的是调查短期 DAPT 对这些患者的疗效和安全性。在这项研究中，检索了来自 PubMed、EMBASE 和 Cochrane 图书馆的随机对照试验，以比较短期 DAPT（6 个月或更少）与长期 DAPT（12 个月或更长）对植入新药物的患者的疗效和安全性。从开始到2020年9月，东亚地区的新一代药物洗脱支架。主要疗效结局是全因死亡，主要安全性结局是大出血，次要结局包括心血管死亡、心肌梗塞、明确或可能的支架血栓、和中风。共有 6 项随机对照试验，涉及 15,688 名患者，符合纳入标准；全因死亡的发生率没有显着差异[风险比（RR），1.03； 0.76–1.39； P = 0.856）]、心血管死亡（RR，0.83；0.55-1.24； P = 0.361）、心肌梗塞（RR，0.97；0.72-1.31； P = 0.853）、明确或可能的支架内血栓形成（RR，1.52；0.83-） 2.78； P = 0.170），以及短期和长期 DAPT 之间的卒中（RR，0.90；0.61–1.31； P = 0.574）。然而，两组之间大出血风险存在显着差异（RR，0.64；0.49-0.85； P = 0.002）。与长期DAPT相比，短期DAPT可以降低东亚人大出血的风险，而不增加死亡或缺血的风险（PROSPERO注册，CRD42020213266）。